95 related articles for article (PubMed ID: 12460759)
1. Protein mutagenesis with monodispersity-based quality probing: selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein.
Ristriani T; Nominé Y; Laurent C; Weiss E; Travé G
Protein Expr Purif; 2002 Dec; 26(3):357-67. PubMed ID: 12460759
[TBL] [Abstract][Full Text] [Related]
2. Formation of soluble inclusion bodies by hpv e6 oncoprotein fused to maltose-binding protein.
Nominé Y; Ristriani T; Laurent C; Lefèvre JF; Weiss E ; Travé G
Protein Expr Purif; 2001 Oct; 23(1):22-32. PubMed ID: 11570842
[TBL] [Abstract][Full Text] [Related]
3. A strategy for optimizing the monodispersity of fusion proteins: application to purification of recombinant HPV E6 oncoprotein.
Nominé Y; Ristriani T; Laurent C; Lefèvre JF; Weiss E ; Travé G
Protein Eng; 2001 Apr; 14(4):297-305. PubMed ID: 11391022
[TBL] [Abstract][Full Text] [Related]
4. Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species.
Zanier K; Nominé Y; Charbonnier S; Ruhlmann C; Schultz P; Schweizer J; Travé G
Protein Expr Purif; 2007 Jan; 51(1):59-70. PubMed ID: 17055740
[TBL] [Abstract][Full Text] [Related]
5. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions.
Ristriani T; Masson M; Nominé Y; Laurent C; Lefevre JF; Weiss E; Travé G
J Mol Biol; 2000 Mar; 296(5):1189-203. PubMed ID: 10698626
[TBL] [Abstract][Full Text] [Related]
6. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
Lechner MS; Laimins LA
J Virol; 1994 Jul; 68(7):4262-73. PubMed ID: 8207801
[TBL] [Abstract][Full Text] [Related]
8. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
9. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6.
Ristriani T; Nominé Y; Masson M; Weiss E; Travé G
J Mol Biol; 2001 Jan; 305(4):729-39. PubMed ID: 11162088
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
Gardiol D; Banks L
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
[TBL] [Abstract][Full Text] [Related]
11. Strategies for bacterial expression of protein-peptide complexes: application to solubilization of papillomavirus E6.
Sidi AO; Babah KO; Brimer N; Nominé Y; Romier C; Kieffer B; Pol SV; Travé G; Zanier K
Protein Expr Purif; 2011 Nov; 80(1):8-16. PubMed ID: 21777678
[TBL] [Abstract][Full Text] [Related]
12. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
Li X; Coffino P
J Virol; 1996 Jul; 70(7):4509-16. PubMed ID: 8676476
[TBL] [Abstract][Full Text] [Related]
13. Cellular distribution of tumour suppressor protein p53 and high-risk human papillomavirus (HPV)-18 E6 fusion protein in wild-type p53 cell lines.
Sun L; Zhang G; Li Z; Lei T; Huang C; Song T; Si L
J Int Med Res; 2008; 36(5):1015-21. PubMed ID: 18831896
[TBL] [Abstract][Full Text] [Related]
14. One-step affinity purification of fusion proteins with optimal monodispersity and biological activity: application to aggregation-prone HPV E6 proteins.
Bonhoure A; Demenge A; Kostmann C; San José L; De la Cal E; Armisen P; Nominé Y; Travé G
Microb Cell Fact; 2018 Dec; 17(1):191. PubMed ID: 30501645
[TBL] [Abstract][Full Text] [Related]
15. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.
Bernard X; Robinson P; Nominé Y; Masson M; Charbonnier S; Ramirez-Ramos JR; Deryckere F; Travé G; Orfanoudakis G
PLoS One; 2011; 6(10):e25981. PubMed ID: 22046250
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
17. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
18. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Scheffner M; Werness BA; Huibregtse JM; Levine AJ; Howley PM
Cell; 1990 Dec; 63(6):1129-36. PubMed ID: 2175676
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.
Nominé Y; Masson M; Charbonnier S; Zanier K; Ristriani T; Deryckère F; Sibler AP; Desplancq D; Atkinson RA; Weiss E; Orfanoudakis G; Kieffer B; Travé G
Mol Cell; 2006 Mar; 21(5):665-78. PubMed ID: 16507364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
